Vimarsana
Biggest News Aggregation in the World

Page 6 - Hartmutj Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hartmutj Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hartmutj Ehrlich Today - Breaking & Trending Today

Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO - Vimarsana News

Abivax to Present Blood and Rectal Tissue Data from UC Patients Treated with Obefazimod at the 18th Congress of ECCO

Abivax will be presenting a poster on blood and rectal tissue data from ulcerative colitis (UC) patients, confirming the novel mechanism of action of obefazimod based on the upregulation of a single microRNA

Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th - Vimarsana News

Abivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th

EQS-News: ABIVAX / Key word(s): ConferenceAbivax to present blood and rectal tissue data from UC patients treated with obefazimod at the 18th Congress of ECCO 14.02.2023 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax to present blood and rectal tissue data from UC patien...

ABX464's Clinical Benefits for Inflammatory Diseases Revealed in Review - Vimarsana News

ABX464's Clinical Benefits for Inflammatory Diseases Revealed in Review

A review study has published the mechanisms and benefits of Abivax's ABX464 to treat inflammatory diseases, including ulcerative colitis.

ABX464 Keeps UC Patients in Remission Over Time, Phase 2 Data Show - Vimarsana News

ABX464 Keeps UC Patients in Remission Over Time, Phase 2 Data Show

ABX464 continues to be effective over time at keeping patients with moderate-to-severe ulcerative colitis in clinical remission, data show.

Abivax Completes Enrollment for Ulcerative Colitis Trial Testing ABX464 - Vimarsana News

Abivax Completes Enrollment for Ulcerative Colitis Trial Testing ABX464

Abivax completed patient enrollment ahead of schedule for a trial testing ABX464 for people with moderate to severe ulcerative colitis.